Share this page
www.indivumed.com/news/precision-oncology-starts-with-precision-insights/
Precision Oncology starts with Precision Insights
Successful drug discovery relies on tumor and matched normal tissue samples that preserve tumor biology as close to its original state as possible. This integrity, combined with analytical, computational, and biochemical expertise enables the discovery of novel therapeutic targets and drug candidates.
Since Indivumed's founding over 20 years ago, we have prioritized high-quality samples as the cornerstone of our business. The latest article from our founder and CEO, Prof. Dr. Hartmut Juhl, recently published in the Winter 2024 edition of the European Biotechnology Magazine, refers about our unique database which allows for a full multi-omic view of cancer biology.